Current Status on Medication of Elderly Inpatients with Chronic Heart Failure in a Hospital
Objective To analyze the current status on the medication of elderly inpatients with chronic heart failure(CHF).Methods A total of 417 elderly patients(≥65 years)with CHF admitted to the hospital from June 2018 to June 2023 were selected.The variety of drugs used by the patients at admission and discharge was counted,and the polypharmacy(≥five kinds of drugs)therapy was analyzed;all drugs used were divided into CHF-related drugs,non-CHF cardiovascular drugs and non-cardiovascular drugs,and the proportions of the three were calculated.The variety of drugs used by patients during hospitalization,the commonly-used drug category and specific variety at admission and discharge were counted.Results The polypharmacy therapy rate of patients on admission was 50.84%,with CHF-related drugs,non-CHF cardiovascular drugs and non-cardiovascular drugs accounting for 28.56%,21.42%,50.02%,respectively;the polypharmacy therapy rate of patients at discharge was 54.92%,with the above three drugs accounting for 32.73%,19.45%,47.82%,respectively.Five to nine varieties of drugs were most commonly used by patients at admission and discharge(26.62%,31.65%).The three categories of drugs commonly used by patients during hospitalization were β-receptor blockers,angiotensin-converting enzyme inhibitors(ACEIs)and platelet aggregation inhibitors(aspirin).At admission and discharge,β-receptor blockers and loop diuretics were the most common CHF-related drugs,platelet aggregation inhibitors(aspirin)and statins were the most common non-CHF cardiovascular drugs,proton pump inhibitors,electrolyte supplements and multivitamins were the most common non-cardiovascular drugs;moreover,the usage rates of the above drugs were higher at discharge than those on admission.Conclusion The polypharmacy therapy rate of elderly patients with CHF in this hospital is high at admission and discharge,with non-cardiovascular drugs accounting for a large proportion.We should pay close attention to the rationality and safety of relevant medications in clinical practice,and it is necessary to formulate relevant strategies for supervision.
elderly patientchronic heart failureinpatientpolypharmacy therapycardiovascular drugspharmaceutical care
万方数据
维普
